Scaling clinical manufacturing of cell therapies from a few patient doses to thousands remains a major industry challenge. Scaling-out increases the number of parallel production units, but traditional workflows such as T-flasks require extensive space, labor, and manual handling. As production expands, complexity grows across logistics, traceability, and GMP compliance, while scaling-up to larger systems can introduce variability and disrupt culture conditions. Key strategies to address these barriers include:
-
Closed and automated processing to reduce contamination risk and manual workload
-
More space- and labor-efficient culture formats to replace thousands of open vessels
-
Standardized scalable systems to maintain consistent quality across batches
-
Process intensification approaches to support GMP-ready manufacturing at larger volumes
